Stock Detail
$HIMS
Healthcare · 34 tracked mentions in the last 90 days across 13 creators.
Valuation and creator stance reflect the last 90 days. The mention feed below shows the latest tracked mentions across all history.
HIMS leans undervalued across 4 creators and 5 classified valuation claims, with 3 direct claims carrying most of the signal.
Creator Evidence
Why creators say this
Explicit claim • strong conviction • basis: price target upside
HIMS to $100 is inevitable
Explicit claim • strong conviction • basis: multiple relative
Hims and hers... Hims & Hers Health is down over 50% from all time highs... but it's one of my favorite opportunities in the market right now because the technicals are setting up for a massive breakout and the fundamental tailwinds are aligning.
Explicit claim • strong conviction • basis: fair value gap
Discounted free cash flow analysis suggests a fair value around $29 per share. Stock is down ~30% for the year, presenting a potential value opportunity below $20.
Implied claim • strong conviction • basis: growth vs multiple
The fundamental transition happening inside the business is just too strong to ignore. You have 59% top-line revenue growth, a clear, proven inflection into sustainable profitability with real cash generation, and that transformative Novo Nordisk deal completely rewrites their risk profile for the better.
Mention History
Latest mentions across all history
Feed